Journal of Molecular Biology最新文献

Drug repurposing is a widely adopted strategy aimed at identifying new therapeutic uses for drugs, offering a faster and more cost-effective alternative to traditional drug development. While the approach has gained significant traction, most existing computational tools are either focused on narrow analytical tasks, require extensive coding expertise or are disease-specific. To address these limitations, we present Repurposing Drug Explorer (ReDEx) - a user-friendly, zero-code platform that streamlines drug repurposing analysis through multiple interactive modules. ReDEx enables the exploration of drug-disease relationships using chemical structure-similarity-based, network-based, and functional methods within an integrated interface. Applied to Bipolar Disorder (BD), after excluding 3 of the 23 FDA approved/investigational drugs for BD, ReDEx successfully recovered all 3 in the top 15 out of 28,189 candidates. ReDEx is offered through a web interface on the Enalos Cloud Platform, enabling users to investigate individual drugs, diseases, or drug-disease pairs without programming skills.

The majority of the Earth's microbial biomass is found in high pressure environments, raising the question of how protein sequences adapt to such environments. Pressure adaptation is more complex, and less well-understood, than adaptation to extreme temperatures since in high pressure environments, these two thermodynamic parameters are often coupled, as in the cold deep-sea or at hydrothermal vents. To begin to address this question, we investigated the functional and folding properties of an exonuclease, Cnase, from the first Gram positive piezophile to be sequenced, Carnobacterium sp. AT7, isolated at 2500 m depth and at ∼2 °C in the Aleutian trench in the North Pacific. We find that Cnase is a bonafide exonuclease, despite its high negative charge. We also find that Cnase largely conserves the structure and folding mechanism of its mesophilic and well-studied homolog, staphylococcal nuclease, Snase, despite significant differences in their sequences.

PDB-IHM is a branch of the Protein Data Bank (PDB), a Worldwide Protein Data Bank (wwPDB) Core Archive, that expands its scope by allowing for additional biomolecular structure representations and types of experimental information (i.e., integrative/hybrid structure models). As of October 2025, PDB-IHM contained 374 entries, benefitting from multi-scale and multi-state representations and 17 types of experimental data. These structure models are assigned PDB accession codes and are archived alongside other experimental structures in the PDB. Rigorous interpretation of a structure model requires assessment of underlying data quality, consistency with the input data, and estimates of positional uncertainty of its components. Herein, we present the IHMValidation pipeline (https://validate.pdb-ihm.org; https://github.com/salilab/IHMValidation) based on recommendations from the wwPDB Integrative Methods Task Force plus the small-angle scattering (SAS), chemical crosslinking mass spectrometry (crosslinking-MS), and cryo-electron microscopy and tomography (3DEM) communities. The IHMValidation report (available in both PDF and HTML formats) comprises six sections: (i) overview; (ii) model details; (iii) data quality assessments; (iv) local geometry assessments (i.e., model quality); (v) fit of the model to the data used to generate it; and (vi) fit of the model to the data used for validation. Future expansions of the IHMValidation pipeline will: (i) reflect recommendations coming from additional experimental communities, including Förster resonance energy transfer (FRET) and hydrogen/deuterium exchange MS (HDX-MS); (ii) include other validation criteria, such as Bayesian likelihoods for the data; and (iii) represent estimates of structure model uncertainty based on the variation among alternative models satisfying input data.